These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 35418778)

  • 1. CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma.
    Li Z; Feng Y; Li P; Wang S; Liu X; Xia S
    Int J Gen Med; 2022; 15():3809-3826. PubMed ID: 35418778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying
    Xiang X; Gao LM; Zhang Y; Zhu Q; Zhao S; Liu W; Ye Y; Tang Y; Zhang W
    PeerJ; 2023; 11():e16618. PubMed ID: 38099311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.
    Zhang C; Li Z; Qi F; Hu X; Luo J
    Ann Transl Med; 2019 Nov; 7(22):648. PubMed ID: 31930049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with
    Fu J; Li Y; Li C; Tong Y; Li M; Cang S
    Transl Cancer Res; 2021 Sep; 10(9):3963-3978. PubMed ID: 35116695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma.
    Li L; Li J
    Front Oncol; 2023; 13():1128785. PubMed ID: 36959799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma.
    Jia H; Tang WJ; Sun L; Wan C; Zhou Y; Shen WZ
    Front Genet; 2022; 13():1017866. PubMed ID: 36699466
    [No Abstract]   [Full Text] [Related]  

  • 8. Glycolysis Define Two Prognostic Subgroups of Lung Adenocarcinoma With Different Mutation Characteristics and Immune Infiltration Signatures.
    Huo C; Zhang MY; Li R; Liu TT; Li JP; Qu YQ
    Front Cell Dev Biol; 2021; 9():645482. PubMed ID: 34368114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon Cancer.
    Zhou Z; Xie X; Wang X; Zhang X; Li W; Sun T; Cai Y; Wu J; Dang C; Zhang H
    Front Genet; 2021; 12():623424. PubMed ID: 33664769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
    Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
    Front Immunol; 2022; 13():943389. PubMed ID: 36003381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 12. Systemic immune microenvironment and regulatory network analysis in patients with lung adenocarcinoma.
    Liu L; Xu S; Huang L; He J; Liu G; Ma S; Weng Y; Huang S
    Transl Cancer Res; 2021 Jun; 10(6):2859-2872. PubMed ID: 35116596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
    Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
    Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma.
    Ouyang R; Li Z; Peng P; Zhang J; Liu J; Qin M; Huang J
    Int J Med Sci; 2021; 18(3):685-694. PubMed ID: 33437203
    [No Abstract]   [Full Text] [Related]  

  • 15. Association of
    Jia M; Yao L; Yang Q; Chi T
    Front Oncol; 2020; 10():168. PubMed ID: 32154170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma.
    Ma X; Xie M; Xue Z; Yao J; Wang Y; Xue X; Wang J
    Comput Biol Med; 2022 Dec; 151(Pt A):106213. PubMed ID: 36306573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.
    Feng Z; Yin Y; Liu B; Zheng Y; Shi D; Zhang H; Qin J
    Cancer Control; 2022; 29():10732748221076682. PubMed ID: 35212236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between tumor mutation burden and immune infiltration in ovarian cancer.
    Fan S; Gao X; Qin Q; Li H; Yuan Z; Zhao S
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107126. PubMed ID: 33189611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.
    Lin J; Lin Y; Huang Z; Li X
    Comput Math Methods Med; 2020; 2020():8836493. PubMed ID: 33273963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.